The Heart Protection Study: High-risk patients benefit from statins, regardless of LDL-C level

被引：14
|
作者：
Gurm, HS
Hoogwerf, B
机构：
[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[2] Cleveland Clin Fdn, Dept Endocrinol & Metab, Cleveland, OH 44195 USA
[3] Cleveland Clin Fdn, Sect Prevent Cardiol, Cleveland, OH 44195 USA
[4] Cleveland Clin Fdn, Internal Med Residency Program, Cleveland, OH 44195 USA
来源：
CLEVELAND CLINIC JOURNAL OF MEDICINE | 2003年 / 70卷 / 11期
关键词：
D O I：
10.3949/ccjm.70.11.991
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The landmark Heart Protection Study (Lancet 2002; 360:7-22) found benefit in treating subjects at high risk of a coronary event with simvastatin 40 mg daily, regardless of baseline low-density lipoprotein cholesterol level and in all subgroups, including women and the elderly. The study found no benefit of simvastatin therapy in preventing noncardiac events (eg, dementia, osteoporotic fractures), and no negative effects, such as an increase in cancer, respiratory disease, or suicide.
引用
收藏
页码：991 / 997
页数：7
相关论文
共 50 条
  • [1] Current Choice for LDL-C Lowering in High-Risk CVD Patients Intolerant to Statins
    Fras, Zlatko
    CURRENT VASCULAR PHARMACOLOGY, 2021, 19 (04) : 398 - 402
  • [2] METABOLIC CAUSES OF HIGH-RISK LDL CHOLESTEROL (LDL-C)
    VEGA, GL
    GRUNDY, SM
    DENKE, MA
    ARTERIOSCLEROSIS, 1989, 9 (05): : A709 - A710
  • [3] Under-treated high-risk patients: identifying patients in high-risk subgroups and treating them to LDL-C targets
    Schuster, H
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2005, 7 (0A) : A20 - A28
  • [4] THE REAL EXPERIENCE OF REACHING AN EXTREMELY LOW LDL-C LEVEL IN HIGH RISK PATIENTS
    Korneva, V. A.
    Kuznetsova, T.
    ATHEROSCLEROSIS, 2022, 355 : E175 - E175
  • [5] Fluvastatin additional benefit beyond LDL-C reduction: A comparison of cardiovascular events risk in patients with the same level of on treatment LDL
    Bogaerts, K
    Tsonaka, S
    Rizopoulous, D
    Lessafre, E
    Gimpelevvicz, C
    Logan, JO
    Bortolini, M
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 99 - 99
  • [6] Comparing the expected benefit of plasma cholesterol reduction with or without LDL-C targets in a high-risk, healthy population
    Cesena, F. H.
    Laurinavicius, A. G.
    Bittencourt, M. S.
    Conceicao, R. D.
    Santos, R. D.
    EUROPEAN HEART JOURNAL, 2015, 36 : 2 - 2
  • [7] Meta-analysis: Lowering LDL-C levels using statins reduces major vascular events regardless of baseline risk
    Jain, Meera
    Rosenberg, Mark
    ANNALS OF INTERNAL MEDICINE, 2012, 157 (08)
  • [8] ALIROCUMAB IN HIGH-RISK PATIENTS WITH BASELINE LDL-C ≥160 MG/DL: FINDINGS FROM THE COMPASSIONATE USE PROGRAM
    Glueck, Charles J.
    Brown, Alan
    Goldberg, Anne
    McKenney, James
    Kantaros, Louis
    Stewart, John
    Elassal, Joseph
    Koren, Andrew
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 155 - 155
  • [9] SOLAR: Initial rosuvastatin superior to atorvastatin, simvastatin for reaching LDL-C goals in high-risk patients
    不详
    FORMULARY, 2007, 42 (08) : 496 - 496
  • [10] Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins: Results From Rose Clinical Trial
    Nicholls, Stephen J.
    Ditmarsch, Marc
    Kastelein, John J., Jr.
    Rigby, Scott P.
    Kling, Douglas
    Curcio, Danielle L.
    Alp, Nicholas J.
    Davidson, Michael H.
    CIRCULATION, 2021, 144 (25) : E576 - E576
12345